Venue
Konzerthaus Freiburg
Konrad-Adenauer-Platz 1
79098 Freiburg im Breisgau

Congress Chairmen
Prof. Dr. Peter Angele &
Prof. Dr. Philipp Niemeyer

Fiscal Organiser, Congress & Exhibition Management
Intercongress GmbH
Ingeborg-Krummer-Schroth-Str. 30
79106 Freiburg
fon +49 761 69699-242
fax +49 761 69699-11

Registration Fees
Please register online at
www.evidence-in-surgery.com

Pass Reduced: 190 EUR
(resident, physiotherapist)

Pass Regular: 290 EUR
(medical doctor)

Pass Plus: 390 EUR
(including access to the business lounge, networking dinner, free wardrobe)

All passes include coffee and lunch breaks.

www.EVIDENCE-IN-SURGERY.com
Dear Colleagues, Ladies and Gentlemen,

The question of clinical and scientific evidence is a topic that is increasingly gaining importance in operative medicine from various aspects. As surgeons and scientists, we question our daily actions and strategies and compare them with other methods in order to participate in the further development and improvement of therapeutic concepts. On the other hand, our treatments are increasingly being questioned by patients and payers, who also demand proof of scientific evidence as the basis for their decision and also for the acceptance of therapies in the reimbursement systems.

We would like to take account of this aspect and this development on 5 and 6 October in Freiburg with a new and innovative congress entitled „Evidence in Knee Surgery“ and in the first year of the event focus on the „cartilage repair“ topic. This also represents a very well-suited subject area - also due to the regulatory requirements and the problems of reimbursement - in order to discuss the topic of evidence and to draw common insights and conclusions.

The cross-border relevance of the topic we would like to take into account through the international design of the congress and discuss specifically differences between different countries and their relevance to the clinic. Here not only clinically active colleagues, but also scientists, industrial workers and politicians with involvement in the reimbursement of therapies are invited as speakers, since all aspects and perspectives should be taken into account.

In addition to the classic lectures, the congress will be supplemented by an interactive workshop and a discussion forum on 4 topic blocks aimed at working towards a consensus and summarizing statements of the participants and experts. In this way a practical utility value is to be achieved through direct discussion, which extends beyond the duration of the congress by publication of the consensus states.

We would be very happy if you'll come to Freiburg on 5 and 6 October 2018 to discuss with us.

Prof. Dr. Peter Angele & Prof. Dr. Philipp Niemeyer
Friday, 5 October

11:30 – 12:30 SESSION 2
Cartilage Treatment | Co-Morbidities
M. Hirschmann & B. Johnstone
15’ What do we know about the role of the meniscus in Cartilage Repair M. Hirschmann (Bruderholz)
15’ What do we know about joint hemostasis in Cartilage Repair B. Johnstone (Portland)
15’ Influence of Alignment in Cartilage Repair G. Bode (Freiburg)
15’ Ligamentous Insufficiency and Cartilage J. Zielner (Regensburg)
12:30 – 13:30 NETWORKING & INDUSTRIAL EXHIBITION

13:30 – 14:30 SESSION 3
Cartilage Repair | Scientific Evidence Non-Surgical treatment of Early OA and Cartilage Defects
B. Wondrasch & T. Tischer
15’ Evidence of Physiotherapy for Treatment of Early OA B. Wondrasch (St. Pölten)
15’ Evidence of the Role of Nutrition in Early OA N.N. (xxxx)
15’ Sport following Cartilage Repair: What is realistic? What can a patient expect G. Welsch (Hamburg)
15’ Present Evidence for PRP in Early OA and Cartilage Defects T. Tischer (Rostock)
14:30 – 15:30 WORKSHOPS
15:30 – 16:00 NETWORKING & INDUSTRIAL EXHIBITION

16:00 – 17:00 SESSION 4
Cartilage Repair | Scientific Evidence “Cell based” versus “Bone Marrow Stimulation”
G. Knutsen & T. de Windt
10’ What we learned from the KNUTSEN trial G. Knutsen (Tromsoe)
10’ What we learned from the TIGENIX and MACI trial T. de Windt (Utrecht)
10’ What we learned from the CO.DON and TETEC trial S. Fickert (Straubing)
10’ What we learned from the German Registry P. Niemeyer (Munich)
10’ What we learned from the ICRS Registry L. Biant (Manchester)
10’ Experiences from the ACTIVE Trial N.N. (xxxx)

17:30 – 18:30 SESSION 5
Cartilage Repair | Regulation and Scientific Evidence
S. Nehrer & P. Niemeyer
15’ Regulatory Authorities: How we judge about scientific evidence M. Schüssler-Lenz (Langen)
15’ Reimbursement Authorities (NICE): How reimbursement authorities judge about reimbursement NICE Mitarbeiter
15’ Reimbursement Authorities (GBA): How reimbursement authorities judge about reimbursement T. de Windt (Utrecht)
15’ Discussion
19:30 NETWORKING EVENING
Saturday, 6 October

8:30 – 9:30 SESSION 6
Cartilage Repair | Patient Selection
P. Kreuz & I. Martin

10’
Scientific Evidence: How does age influence the outcome? P. Kreuz (Bad Tölz)

10’
Scientific Evidence: How can we measure joint degeneration and the availability of the patient for Cartilage Repair? P. Angele (Regensburg)

10’
Preclinical Evidence: Is there a way to determine patient availability on a molecular level? C. Hulme (Shropshire)

15’
Future Perspectives: How can we further improve J. Martin (Basel)

9:30 – 10:30 SESSION 7
Cartilage Repair | “Cell-free” Biomaterials
E. Kon & G. Spahn

15’
Scientific Evidence about indications for “Cell-free” Biomaterials in Cartilage Repair E. Kon (Milano)

15’
What products are available? What Evidence do we have? D. Günther (Hannover)

15’
Defining indications for “Cell-free” Biomaterials G. Spahn (Eisenach)

15’
Complications following “Cell-free” therapeutical strategies: What is known? J. Peska (Freiburg)

10:30 – 11:30 WORKSHOPS

11:30 – 12:00 NETWORKING & INDUSTRIAL EXHIBITION

12:00 – 12:45 CONSENSUS & VOTING SESSION

14:15 – 15:15 SESSION 8
Cartilage Repair | Concomitant Surgeries | Registry Data
A. Wilson & C. N. Engen

15’
Does Patients in Prospective Trials represent Clinical Every Day Indications C. N. Engen (Oslo)

15’
ACL Registry: Cartilage Repair and ACL reconstruction What can we measure about combined therapies? M. Lind (Aarhus)

15’
Align P. Niemeyer (Munich)

15’
UKKOR Experiences: How should we combine CR and Osteotomies basend upon the UK experience A. Wilson (Basingstoke)

15:15 – 15:55 SESSION 9
Short presentations from the Consensus Groups
P. Angele & P. Niemeyer

10’
Group 1: European Strategy

10’
Group 2: Early OA

10’
Group 3: Adjacent Injections

10’
Group 4: Clinical Needs

11:30 – 13:00 CONSENSUS GROUPS AND DISCUSSIONS

11:30 – 12:00 NETWORKING & INDUSTRIAL EXHIBITION

12:00 – 12:45 CONSENSUS & VOTING SESSION